SEARCH | COVID-19 LST 12/1219

Discovery of human ACE2 variants with altered recognition by the SARS-CoV-2 spike protein

BLUF

Summary

Figures

I'm a paragraph. Click here to add your own text and edit me. It's easy.

Possible Human-to-Dog Transmission of SARS-CoV-2, Italy, 2020

BLUF

Summary

Figures

I'm a paragraph. Click here to add your own text and edit me. It's easy.

More on SARS-CoV-2 Infection after Vaccination in Health Care Workers

BLUF

Summary

Figures

I'm a paragraph. Click here to add your own text and edit me. It's easy.

BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants

BLUF

Summary

Figures

I'm a paragraph. Click here to add your own text and edit me. It's easy.

Remdesivir for coronavirus disease 2019 (COVID-19): a systematic review with meta-analysis and trial sequential analysis of randomized controlled trials

BLUF

Researchers from University of Manitoba, Canada conducted a systematic review and meta-analysis on 5 studies examining remdesivir use in COVID-19 treatment (Table 1). Results indicated that a 10-day course of 100 mg remdesivir did not reduce all-cause mortality (RR 0.94, 95% CI 0.82-1.07; I^2=0%) or clinical progression of COVID-19 (RR 0.82, 95% CI 0.40-1.66; I^2=0%) (Figure 3). A 5-day course improved clinical progression (RR 1.05, 95% CI 1.01–1.10), but trial sequential analysis was inconclusive (Figure 4). This suggests that despite use of remdesivir for COVID-19 patients, no significant benefits are seen after 10 days of use in comparison to no treatment/placebo.

Summary

Figures

I'm a paragraph. Click here to add your own text and edit me. It's easy.

Scroll Down to Load More